Redeye initiates coverage of Inhalation Sciences (ISAB), a Swedish medtech company whose technologically sophisticated PreciseInhale system enables scientists to efficiently measure how inhaled particles behave in human lungs. We argue that the share offers investors exposure to exciting growth in the inhalation therapies market and see the current share price as an attractive entry point for the long-term investor.

Link to the analysis